Invitrogen Launches Revolutionary New Cloning Product; Echo Cloning System Enables Fast, Reliable Cloning Into Multiple Expression Systems
SAN DIEGO, Dec. 6 /PRNewswire/ -- Invitrogen Corporation (Nasdaq:
today introduced the Echo(TM) Cloning System, which makes possible fast and
reliable cloning of any gene into multiple expression vectors. The Echo
System dramatically reduces the time and effort associated with cloning
for expression analysis, speeding the drug research and discovery process.
The first commercially available system of its kind, the Echo System
brings Invitrogen's highly-efficient TOPO(R) Cloning technology and its
advanced expression systems together with a novel univector
system developed by Stephen J. Elledge, Ph.D., professor of biochemistry at
Baylor College of Medicine in Houston. Baylor will be paid a royalty under a
license agreement with Invitrogen.
"Echo Cloning makes obsolete the need for traditional subcloning, a
troublesome, time-consuming step in gene expression and analysis," said Lyle
Turner, Chairman and CEO of Invitrogen. "Using Invitrogen's efficient TOPO
Cloning technology, scientists now need to clone and sequence a construct only
once. The clone is then recombined or 'echoed' into other expression vectors
-- ranging from bacterial to mammalian cells -- simultaneously. The process
works on any gene and can be automated, providing a tremendous time saver for
The Echo System can be used by any scientist who wants to accelerate
cloning process, according to Turner, but could prove especially valuable for
high-volume users such as pharmaceutical companies and large research foundations who can use the system to facilitate high-throughout gene cloning
and reduce the time and costs associated with identifying and validating new
drug targets and developing new therapeutics.
"The Echo System expands the high-throughput cloning product and
offerings of our Invitrogenomics program by adding high-throughput subcloning
and expression analysis, further accelerating target identification and validation," Turner said.
"Last week, landmark results of the Human Genome Project were
with the completion of the sequencing of human chromosome 22," said Turner.
"This significant development marks just the beginning of the research that
will need to be done. The genes that are identified from this chromosome and
subsequent structural analysis of chromosomes will provide scientists with the
knowledge of the gene sequence. Broad, new functional studies will now need
to be mounted to find out what these genes can do individually, and the Echo
System will allow scientists to quickly clone and express these genes into
multiple host systems and make proteins for experimentation. A process that
was previously slow and unreliable now becomes quick and accurate thanks to
the new Echo System."
Invitrogen's TOPO Cloning is used in functional genomics research
gene-based drug discovery and has become the dominant PCR (Polymerase Chain
Reaction) cloning technique among researchers worldwide. Invitrogen holds
exclusive worldwide commercial rights to the TOPO Cloning patent, granted to
the Sloan-Kettering Institute for Cancer Research, for the life of the patent,
which expires in 2015.
"We are giving our customers the power of TOPO at the first step in
cloning process," said Turner, "and with the addition of Echo Cloning, plasmid
fusions can be quickly prepared for expression in Invitrogen's expression
systems or any other expression system being used by the customer."
For more information on the Echo System, visit the following page on
Invitrogen's web site at http://www.invitrogen.com/catalog_echo.html.
Invitrogen develops, manufactures and markets research tools in kit
and provides other research products and services to corporate, academic and
government entities. The company's kits and products simplify and improve
gene cloning, gene expression and gene analysis techniques as well as other
molecular biology activities. Through its Invitrogenomics program, the company also provides gene cloning and expression services on a contract basis
using its high-throughput gene cloning and expression technology. Invitrogen
is headquartered in San Diego, California and operates European facilities in
The Netherlands and Germany. More information on Invitrogen can be found on
the company's Web site at http://www.invitrogen.com.
Certain statements contained in this news release are
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995. Statements relating to efficiency, usefulness, automation, speed and
cost savings of existing and new products and future uses of those products
are prospective. Such forward-looking statements are subject to a number of
risks, uncertainties and other factors that could cause actual results to
differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but
are not limited to, successful development, commercialization and market
acceptance of new products and services, proper licensing of
competition as well as other risks and uncertainties detailed from time to
time in Invitrogen Corporation's Securities and Exchange Commission filings.
SOURCE Invitrogen Corporation
Web Site: http://www.invitrogen.com
(Today's News) (Company News On-Call) (Search) (Feature News) (Automotive)
(Energy)(Entertainment) (Financial) (Health/Biotech) (Hispanic) (Latin America) (Sports)
(Technology)(Washington) (Mountain News) (PRN Products & Services) (Ask PRN) (Links)
-- David A. Kekich LifeEx Technologies, LLC 175 Whispering Pines Estates Johnstown, PA 15905 USA Tele. 814-255-6005/Fax 814-255-3418 http://www.LifeEx.com ******************************* Bringing You Cutting Edge Life Extension Technologies ********************************